Navigation Links
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Date:11/30/2009

PARIS, November 30 /PRNewswire-FirstCall/ --

- First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European member states. This approval follows the European Commission positive opinion issued on September 25, 2009 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine agency (EMEA).

Multaq(R) is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

Multaq(R) discovered and developed by sanofi-aventis is the first anti-arrhythmic drug approved in the European Union that has shown a clinical benefit to reduce cardiovascular hospitalizations or death from any cause in patients with AF/AFL as described in the ATHENA trial.

"The approval of Multaq(R) in the European Union is important news for atrial fibrillation patients who will now have access to a new treatment approach," said Marc Cluzel, MD, Executive Vice President, Research and Development, sanofi-aventis. "The approval of Multaq(R) is the result of more than 15 years of research and development conducted by sanofi-aventis and supported by the commitment of the experts involved in the clinical development program and AF patients participating in the trials."

The use of dronedarone in unstable patients with NYHA class III and IV heart failure is contraindicated. Because of limited experience in stable patients with recent (1 to 3 months) NYHA class III heart failure or with Left Ventricular Ejection Fraction (LVEF) <35%, the use o
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
9. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
10. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... quarter ended June 30, 2015 on Tuesday, August 4, ... Regulus will host a conference call and webcast ... Daylight Time to discuss its second quarter 2015 financial ...
(Date:7/28/2015)... -- Express Scripts Holding Company (Nasdaq: ESRX ) announced ... stockholders of $600.1 million, or $0.88 per diluted share.  ... 4, were $1.44 for the second quarter. 1  ... healthcare are validating the need for size and scale," ... what matters most is how that size and scale ...
(Date:7/28/2015)... 2015 On the afternoon of August 11, ... CPI International, Inc. (CPI), plans to file its Form ... with the Securities and Exchange Commission and to issue ...  At 11 a.m. (EDT) on Wednesday, August 12, 2015, ... with this release that will be Web cast simultaneously ...
Breaking Medicine Technology:Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25CPI International To Announce Third Quarter 2015 Financial Results 2
... to 50% of Patients and Was,Well-Tolerated ,PRINCETON, NJ, ... Network),-- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical,company ... from its completed Phase 2/3 study of liarozole,in ... 1 in 200,000) which is characterized by a ...
... Spain, June 15, 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squibb ... safety of ORENCIA(R) (abatacept) from the open-label,phase ... with juvenile,idiopathic arthritis (JIA) who have had ... anti- rheumatic drugs (DMARDs), such,as methotrexate (MTX) ...
Cached Medicine Technology:Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 2Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 3Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 4Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6
(Date:7/29/2015)... ... July 29, 2015 , ... For the second year in ... in the list of the 50 fastest growing companies in Jacksonville. This annual list ... community. On July 16th, a team of Vast Bridges staffers were on hand to ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... MD (PRWEB) , ... July 29, 2015 , ... A ... Get Checked for Skin Cancer ," discussed the importance of having regular skin cancer ... a person has excessive exposure to ultraviolet rays. When caught early, skin cancer is ...
(Date:7/29/2015)... ... , ... Several years ago, in order to be in the strongest position ... proactive stance and began planning the Children’s Village consisting of six homes. , Two ... the third home. , “We are very pleased to have received the $500,000 grant ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto native ... late 1970s, Dr. Cottrell has been making predictions about the economy, politics, social ... many of these prognostications. He warns that extreme weather conditions and increased earthquake ...
Breaking Medicine News(10 mins):Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
... Thomas Lescault, president of SCAN Long Term Care and ... the new Arizona Association of Health Plans. "The new ... providing accessible, affordable healthcare here in Arizona," said Lescault. ... the Arizona Legislature and the governor,s office in adjusting ...
... today by Every Child By Two:The U.S. Court of ... the causes of autism. The three judges ruled ... thimerosal-containing vaccines, does not cause autism. The ruling ... failed to show a link between vaccines and the ...
... don,t respond to current treatments, study finds , , ... shows promise against psoriatic arthritis (PA), according to a ... and North America. , PA affects about 11 percent ... the skin and joints. Some patients don,t respond to ...
... rhinoviruses now sequenced, could lead to new treatments, researchers ... medical breakthrough: a cure for the common cold. , ... a significant step in that direction: the genetic codes ... nasal infections. , "There has been brilliant work done ...
... Spencer Inc.,(NYSE: CSA ) announces the promotion ... the Company,s wholly owned subsidiary, Erdman, A Cogdell,Spencer Company ... Company,s Atlanta office, Ms. Dorr will focus on developing,and ... and development projects in the Region, which includes Georgia,Florida, ...
... N.J., Feb. 12 The Journal of Commerce Conferences, ... will take place May 12 and 13, 2009, at ... the event is "Linking Up the Cold Chain," and ... refrigerated and frozen cargo, will be the conference host.Cool ...
Cached Medicine News:Health News:SCAN's Thomas Lescault Elected President of New Arizona Association of Health Plans 2Health News:Federal Court Declares Vaccines Do Not Cause Autism 2Health News:Drug Reduces Inflammatory Arthritis Symptoms, Lesions 2Health News:Genetic Code of Common Cold Cracked 2Health News:Genetic Code of Common Cold Cracked 3Health News:Cogdell Spencer Announces Dorr as President of the Southeast Region 2Health News:Cogdell Spencer Announces Dorr as President of the Southeast Region 3Health News:'Linking Up the Cold Chain' is Focus of The JoC Conferences' First Cool Cargoes Conference, May 12-13, in Portland, Oregon 2Health News:'Linking Up the Cold Chain' is Focus of The JoC Conferences' First Cool Cargoes Conference, May 12-13, in Portland, Oregon 3
... St. Jude Medical is the world ... introducers are used worldwide for permanent ... venous catheter and port implantation, and ... design of St. Jude Medical Peel-Away ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... The OMNILINK®.035 Biliary Stent System is a supportive .035" ... 5.0 - 10.0 mm in lengths of 18 mm, ... - 7.0 mm diameters available in 12 and 16 ... available in 18mm lengths. Two "diameter specific" OMNILINK® ...
Medicine Products: